经皮给药纳米载体及靶向系统治疗类风湿关节炎研究进展

Research Advances on the Therapy of Rheumatoid Arthritis with the Nanotechnology Based on Transdermal Drug Delivery System

类风湿关节炎(RA)是全世界难治性自身免疫疾病,其治疗药物虽不断发展,但病灶药物浓度达不到有效水平导致药物疗效不理想或存在各种毒副反应,因此,基于新技术、新方法研究开发针对RA的安全、高效新型制剂是必要的。研究表明,纳米技术的运用可提高药物生物利用度,经皮给药可改善口服和注射带来的毒副作用。对近年来基于经皮给药系统治疗RA利用的纳米载体进行综述,并阐述在RA病理特征中运用到的靶向策略,思考透皮制剂的改进方法,探讨新型纳米制剂研究现状及存在的问题,从而为制备新型透皮纳米制剂提供参考。

Rheumatoid arthritis(RA)is a systemic,chronic autoimmune disease that is considered to be incurable.Less effective concentration of conventional drugs in the affected joints and more frequent adverse effects of even novel biological agents remain to be therapeutic challengs for RA.Advances in nanobiotechnology have facilitated the development of new classes of therapeutics with a focus on new drug delivery systems.Recent studies have shown that nanocarriers can significantly improve bioavailability of existing,traditional diseasemodifying antirheumatic drugs(DMARS),and transdermal delivery can remarkably decrease toxic effects and adverse reaction of oral administration and injection of drugs.Here,nanomaterials used in the transdermal drug delivery system for RA therapy and target therapeutic strategies in the basic-research aspect of RA as well as the progress and existing issues of current nano-preparations are summarized so as to provide perspectives for further avenues of development and improved method of novel transdermal nanomaterial-loaded drug delivery systems.